FDA panel to review peptide drug rules conflict concerns

A U.S. Food and Drug Administration advisory panel is set to meet in July to consider easing restrictions on a class of unapproved peptide drugs, a move that has drawn scrutiny due to the financial ties many new panel members have to the peptide industry. The agency released the list of participants for the upcoming two-day meeting on Monday, June 29.

The discussion will focus on whether to relax regulatory barriers for several peptides, including BPC-157 and TB-500, which are currently sold in a gray market. These substances are often marketed online and by wellness clinics for purposes like muscle building, injury recovery, and anti-aging, despite limited clinical evidence supporting their safety or effectiveness. They are frequently labeled "for research use only" to skirt drug regulations and are considered doping substances by international sports authorities.

A significant point of controversy is the composition of the newly appointed advisory panel. Unlike previous panels composed primarily of academic researchers, the new group includes more than half a dozen health professionals who run clinics, online businesses, or pharmacies that specialize in peptides and other...